Michał Sapa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michał Sapa has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adam Bucki
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland
2 shared publications - Alicja Gawalska
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 31-008 Cracow, Poland
2 shared publications - Marcin Kołaczkowski
Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland
2 shared publications Agata Siwek
Department of Medicinal Chemistry, Faculty of Pharmacy Jagiellonian University Medical College Krakow Poland
1 shared publication- Aleksander Mendyk
Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
1 shared publication - Andrzej J. Bojarski
Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
1 shared publication
Latest Publications
- 21 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10)
A Dual 5‐HT 7 Receptor Antagonist and Sodium Channel Inhibitor With Antidepressant‐ and Anxiolytic‐Like Activity and Reduced Hepatotoxicity
The aim of this study was to characterize the pharmacological profile of a newly synthesized compound 5 ( R,S) −1‐(5‐{4‐[(1,1'‐biphenyl)‐2‐yl]piperazin‐1‐yl}pentyl)−3',4'‐dihydro‐2' H ‐spiro[imidazolidine‐4,1'‐naphthalene]‐2,5‐dione, designed as a dual‐acting ligand targeting the serotonin 5‐HT 7 receptor and voltage‐gated sodium channels. In vitro studies demonstrated that compound 5 exhibits high affinity for the 5‐HT 7 receptor (K i = 19 nM), comparable to the reference ligand LP‐211, and potent inhibition of sodium channels, markedly stronger than that of phenytoin. Functional assays confirmed that compound 5 acts as a 5‐HT 7 receptor antagonist (K b = 87 nM) with no detectable agonist activity. In addition, the compound showed negligible affinity for the serotonin transporter (SERT), indicating a favorable selectivity profile. Molecular docking studies revealed a stable binding mode of compound 5 within the orthosteric site of the 5‐HT 7 receptor, consistent with known GPCR interaction patterns. Modifications to compound 5 improved its safety by reducing hepatocytotoxicity in HepG2 cells. In vivo behavioral experiments demonstrated significant antidepressant‐like effects in the forced swim test and anxiolytic‐like effects in the four‐plate test in mice.
- 21 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10)
A Dual 5‐HT 7 Receptor Antagonist and Sodium Channel Inhibitor With Antidepressant‐ and Anxiolytic‐Like Activity and Reduced Hepatotoxicity
The aim of this study was to characterize the pharmacological profile of a newly synthesized compound 5 ( R,S) −1‐(5‐{4‐[(1,1'‐biphenyl)‐2‐yl]piperazin‐1‐yl}pentyl)−3',4'‐dihydro‐2' H ‐spiro[imidazolidine‐4,1'‐naphthalene]‐2,5‐dione, designed as a dual‐acting ligand targeting the serotonin 5‐HT 7 receptor and voltage‐gated sodium channels. In vitro studies demonstrated that compound 5 exhibits high affinity for the 5‐HT 7 receptor (K i = 19 nM), comparable to the reference ligand LP‐211, and potent inhibition of sodium channels, markedly stronger than that of phenytoin. Functional assays confirmed that compound 5 acts as a 5‐HT 7 receptor antagonist (K b = 87 nM) with no detectable agonist activity. In addition, the compound showed negligible affinity for the serotonin transporter (SERT), indicating a favorable selectivity profile. Molecular docking studies revealed a stable binding mode of compound 5 within the orthosteric site of the 5‐HT 7 receptor, consistent with known GPCR interaction patterns. Modifications to compound 5 improved its safety by reducing hepatocytotoxicity in HepG2 cells. In vivo behavioral experiments demonstrated significant antidepressant‐like effects in the forced swim test and anxiolytic‐like effects in the four‐plate test in mice.
- 16 June 2023
- Published by Wiley in Molecular Informatics
- Vol. 42 (7)
Application of automated machine learning in the identification of multi‐target‐directed ligands blocking PDE4B, PDE8A, and TRPA1 with potential use in the treatment of asthma and COPD
Asthma and COPD are characterized by complex pathophysiology associated with chronic inflammation, bronchoconstriction, and bronchial hyperresponsiveness resulting in airway remodeling. A possible comprehensive solution that could fully counteract the pathological processes of both diseases are rationally designed multi‐target‐directed ligands (MTDLs), combining PDE4B and PDE8A inhibition with TRPA1 blockade. The aim of the study was to develop AutoML models to search for novel MTDL chemotypes blocking PDE4B, PDE8A, and TRPA1. Regression models were developed for each of the biological targets using “mljar‐supervised”. On their basis, virtual screenings of commercially available compounds derived from the ZINC15 database were performed. A common group of compounds placed within the top results was selected as potential novel chemotypes of multifunctional ligands. This study represents the first attempt to discover the potential MTDLs inhibiting three biological targets. The obtained results prove the usefulness of AutoML methodology in the identification of hits from the big compound databases.
- 16 June 2023
- Published by Wiley in Molecular Informatics
- Vol. 42 (7)
Application of automated machine learning in the identification of multi‐target‐directed ligands blocking PDE4B, PDE8A, and TRPA1 with potential use in the treatment of asthma and COPD
Asthma and COPD are characterized by complex pathophysiology associated with chronic inflammation, bronchoconstriction, and bronchial hyperresponsiveness resulting in airway remodeling. A possible comprehensive solution that could fully counteract the pathological processes of both diseases are rationally designed multi‐target‐directed ligands (MTDLs), combining PDE4B and PDE8A inhibition with TRPA1 blockade. The aim of the study was to develop AutoML models to search for novel MTDL chemotypes blocking PDE4B, PDE8A, and TRPA1. Regression models were developed for each of the biological targets using “mljar‐supervised”. On their basis, virtual screenings of commercially available compounds derived from the ZINC15 database were performed. A common group of compounds placed within the top results was selected as potential novel chemotypes of multifunctional ligands. This study represents the first attempt to discover the potential MTDLs inhibiting three biological targets. The obtained results prove the usefulness of AutoML methodology in the identification of hits from the big compound databases.
- Open Access
- 1 January 2022
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 78 (11) , 607-614
The use of machine learning-based sequential virtual screening in the search of new ligands of 5-HT6 receptor
- 1 January 2022
- Published by Polish Pharmaceutical Society in Farmacja Polska
- Vol. 78 (11) , 607-614
Open AccessThe use of machine learning-based sequential virtual screening in the search of new ligands of 5-HT6 receptor